Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Chronobiology-based Lenvatinib in Thyroid Cancer
NCT06321120Phase 1Recruiting
- Sponsor
- Hadassah Medical Organization
- Start
- Mar 2023
- Primary completion
- Apr 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of lenvatinib in thyroid cancer, sponsored by Hadassah Medical Organization. Primary endpoint: Disease progression or tumor response at 14 weeks. Started Mar 2023; status: recruiting.
02
Drugs
lenvatinib
03
Conditions
thyroid cancer
Beyond the preview
Go deeper on NCT06321120.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06321120.